Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Pharmaceutical combination of an EP4 antagonist and immune checkpoint inhibitors for the treatment of tumours

Pharmaceutical combination of an EP4 antagonist and immune checkpoint inhibitors for the treatment of tumours

US Patent 11590114 · Granted Feb 28, 2023

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

FYN and VEGFR2 kinase inhibitors2025
FYN and VEGFR2 kinase inhibitors2025
FYN and VEGFR2 kinase inhibitors2025
(R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyc2025
(R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyc2025
(R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyc2025
Process for the preparation of (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspir2025
Process for the preparation of (R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspir2025
(R)-4-(1-(1-(4-(trifluoromethyl)benzyl)pyrrolidine-2-carboxamide)cyclopropyl)-be2023
FYN kinase inhibitors2018
FYN kinase inhibitors2018
Anti-ADAMTS-5 antibody, derivatives and uses thereof2017